Acceleron Pharma

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. 
The Company's research focuses on harnessing the power of the TGF-beta protein superfamily, the target-rich area of biology behind the body’s remarkable capacity for cellular growth and repair. Its approach to drug discovery is driven by deep scientific expertise—and an urgency to deliver effective treatments to thousands of patients who have few or no therapeutic options. The Company’s lead product candidate, luspatercept, is being evaluated in two Phase 3 studies in a global partnership with Celgene to treat chronic, sometimes debilitating anemias in myelodysplastic syndromes (MDS) and beta-thalassemia. Acceleron is also advancing clinical programs in neuromuscular disorders and cancer, and preclinical research in fibrotic and other diseases.

Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2004
Size (employees)
121 (est)+19%
Acceleron Pharma was founded in 2004 and is headquartered in Cambridge, US

Key People at Acceleron Pharma

Habib Dable

Habib Dable

President and Chief Executive Officer
Kevin McLaughlin

Kevin McLaughlin

Chief Financial Officer
Steven Ertel

Steven Ertel

Chief Operating Officer
Matthew Sherman

Matthew Sherman

Chief Medical Officer
Ravi Kumar

Ravi Kumar

Chief Scientific Officer
John Quisel

John Quisel

SVP, Business Development and General Councel
Christopher Rovaldi

Christopher Rovaldi

VP, Program Management

Acceleron Pharma Office Locations

Acceleron Pharma has an office in Cambridge
Cambridge, US (HQ)
128 Sidney Street

Acceleron Pharma Data and Metrics

Acceleron Pharma Financial Metrics

Acceleron Pharma's revenue was reported to be $27.8 m in FY, 2016 which is a 53% increase from the previous period.
USD

Revenue (FY, 2016)

27.8 m

Revenue growth (FY, 2015 - FY, 2016), %

53%

Net income (FY, 2016)

(57 m)

EBIT (FY, 2016)

(66.1 m)

Market capitalization (27-Jun-2017)

1.1 b

Closing share price (27-Jun-2017)

31

Cash (31-Dec-2016)

21 m
Acceleron Pharma's current market capitalization is $1.1 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

57.2 m14.6 m18.1 m27.8 m

Revenue growth, %

(74%)24%53%

Operating expense total

50.3 m70.1 m79 m93.9 m

EBIT

7 m(55.5 m)(60.9 m)(66.1 m)

EBIT margin, %

12%(379%)(336%)(238%)

Interest expense

2.1 m922 k

Interest income

39 k83 k512 k1.9 m

Pre tax profit

(21.9 m)(51.3 m)(63.9 m)(57 m)

Income tax expense

(24 k)

Net Income

(21.9 m)(51.3 m)(63.9 m)(57 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

113.2 m176.5 m27.8 m21 m

Inventories

2.2 m2.5 m2.5 m3.9 m

Current Assets

119 m182.3 m110.9 m146.8 m

PP&E

3.7 m3.1 m3.1 m5.2 m

Total Assets

123.7 m186.3 m146.3 m247.6 m

Accounts Payable

885 k724 k875 k1.6 m

Current Liabilities

27.2 m9.3 m14.5 m16.1 m

Additional Paid-in Capital

250.1 m399.8 m416.9 m590.5 m

Retained Earnings

(192.3 m)(243.6 m)(307.5 m)(364.5 m)

Total Equity

57.8 m156.3 m109.3 m225.6 m

Financial Leverage

2.1 x1.2 x1.3 x1.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(21.9 m)(51.3 m)(63.9 m)(57 m)

Depreciation and Amortization

915 k1.1 m1.2 m1.7 m

Inventories

(823 k)(255 k)7 k(1.4 m)

Accounts Payable

(53 k)(161 k)151 k644 k

Cash From Operating Activities

(19.7 m)(53.2 m)(44.2 m)(44.7 m)

Purchases of PP&E

(307 k)(514 k)(959 k)(3.4 m)

Cash From Investing Activities

(307 k)(514 k)(109 m)(108.8 m)

Long-term Borrowings

(3.7 m)(16.3 m)

Cash From Financing Activities

93.5 m117 m4.5 m146.7 m

Interest Paid

1.7 m1.6 m
USDY, 2016

Revenue/Employee

272.3 k

Financial Leverage

1.1 x

Acceleron Pharma Operating Metrics

FY, 2015FY, 2016

Phase III Trials

22

Acceleron Pharma Market Value History

Acceleron Pharma Online and Social Media Presence

Acceleron Pharma Company Life and Culture

You may also be interested in